<DOC>
	<DOC>NCT01021332</DOC>
	<brief_summary>Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.</brief_summary>
	<brief_title>Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms</brief_title>
	<detailed_description>This is an open-label extension study following the double blind 905-CL-055 study</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Completion of 12 weeks doubleblind treatment in Study 905CL055 Any significant PVR volume (&gt;150 mL)</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>Treatment</keyword>
	<keyword>Solifenacin succinate</keyword>
	<keyword>Tamsulosin hydrochloride OCAS</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>EC905</keyword>
	<keyword>Vesomni</keyword>
</DOC>